Clients benefit from our team’s extensive experience with Health Canada, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) to streamline global regulatory pathways. Regulatory approval is achieved through a clear strategy and an execution focused plan. We provide strategic assessments and practical guidance for global markets, building scalable project models tailored to specific needs and budgets.
Our team delivers integrated solutions for international regulatory requirements, clarifying pathways and managing submissions for pharmaceuticals, biologics, and medical devices across North America and Europe. Our strategies are based on direct regulatory experience and agency knowledge, providing sponsors with clear guidance on development, Chemistry, Manufacturing, and Controls (CMC), and clinical requirements.
From initial due diligence to post approval lifecycle management, our CMC Regulatory Compliance specialists prepare, review, and file submissions with precision. We emphasize proactive problem solving to help clients achieve and maintain compliance at every stage of the product lifecycle in all major jurisdictions.
01 / 07
Successful market access starts with a well defined regulatory strategy. We work with clients to identify the most efficient and low risk pathway to approval, tailored to each product’s unique characteristics and business objectives.
We identify and pursue opportunities for expedited development and review to accelerate product timelines.
We continuously monitor the evolving regulatory landscape, providing proactive updates on new guidelines, emerging expectations, and policy changes that may impact product portfolios across FDA, EMA, and Health Canada.
Engaging with health authorities before submission is essential. We prepare, author, and strategically plan for meetings with global agencies, including:
Comprehensive regulatory roadmaps identify optimal submission pathways, target markets, and timelines. These strategies cover the entire product lifecycle, from early development through commercialization and beyond.
02 / 07
Initiating clinical trials requires meticulous preparation and submission of comprehensive applications that satisfy the unique requirements of each jurisdiction.
End-to-end consulting is provided for Clinical Trial Applications (CTA) submissions, including preparation of the application kit, protocol assessment, Investigator’s Brochure review, and ongoing CTA amendments and renewals.
Coordination and preparation of Clinical Trial Applications in accordance with the EU Clinical Trials Regulation (EU CTR 536/2014) and submission via the Clinical Trials Information System (CTIS) are provided. Part I and Part II documentation, timelines, and sponsor interactions are managed by the team.
Ongoing support for CTA amendments, protocol deviations reporting, annual progress reports, and end-of-trial notifications across all three jurisdictions.
Comprehensive preparation and management of Investigational New Drug (IND) submissions to the US FDA are provided. This includes authoring the IND in eCTD format, managing annual reports, and preparing responses to FDA clinical holds or information requests.
Applicable Standards: ICH E6 (GCP), EU CTR 536/2014, FDA 21 CFR Part 312 (IND), FDA 21 CFR Part 812 (IDE), Health Canada Clinical Trial Regulations, ISO 14155 (clinical investigation of medical devices), ICH E2A (clinical safety data management).
03 / 07
The Chemistry, Manufacturing, and Controls (CMC) section is often the most scrutinized part of any regulatory submission. Our CMC Regulatory Compliance specialists provide deep scientific and regulatory expertise to ensure that quality packages are robust, coherent, and submission ready.
Thorough assessment of existing CMC packages against Health Canada, FDA, and EMA expectations is conducted to identify risks, gaps, and opportunities for optimization prior to submission. Analytical methods, manufacturing processes, specifications, and stability data are evaluated to ensure alignment with ICH guidelines and regional expectations.
Authoring of IMPDs for European clinical trial applications is conducted, ensuring alignment with the quality requirements of the EU CTR and preparedness for potential inspections.
Rapid and effective preparation of responses to Health Authority questions and deficiency letters. Our specialists craft scientifically sound, clearly justified arguments to facilitate the swift resolution of queries and to move your application forward.
Assistance is provided with the selection, technical assessment, and qualification of third-party manufacturers and suppliers. Gap analyses are conducted, and remediation support is offered to ensure CMOs meet global GMP and regulatory expectations.
Strategic guidance is provided on Quality by Design (QbD) initiatives, identification of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs), and development of control strategies that support robust manufacturing and regulatory flexibility.
Expert authoring, compilation, and critical review of quality modules are provided across the Common Technical Document (CTD) format.
Applicable Standards: ICH Q1A/E (stability), Q2 (analytical validation), Q3 (impurities), Q6 (specifications), Q7 (API), Q8 (pharmaceutical development), Q9 (quality risk management), Q10 (pharmaceutical quality system), M4 (CTD), FDA 21 CFR Part 211, EU GMP Annex 11 (computerised systems), EU GMP Annex 15 (qualification and validation), Health Canada GMP guidelines (C.02.015 to C.02.029), PIC/S GMP Guide, ISPE Baseline Guides, ASTM E2500 (commissioning and qualification).
04 / 07
Maintaining compliance after approval requires vigilant management of changes and ongoing regulatory obligations. We provide strategic and operational support to ensure that products remain compliant throughout their lifecycle.
Strategic assessment and execution of post-approval changes are provided, including manufacturing site transfers, process improvements, specification updates, and container closure system changes.
Systematic tracking and execution of post-marketing commitments and requirements are provided, ensuring timely fulfillment and regulatory reporting to avoid compliance issues.
Preparation and submission of annual reports, renewals, and other periodic updates are provided.
Design and management of stability studies are provided to support shelf-life extensions, post-approval changes, and ongoing commitment batches. Oversight of protocol development, data review, and statistical analysis is conducted to ensure compliance with ICH Q1A/E requirements.
Applicable Standards: ICH Q1A/E (stability), Q10 (pharmaceutical quality system), FDA 21 CFR Part 314 (NDA/ANDA), EU Variations Regulation (EC) No 1234/2008, Health Canada Post-DIN Changes Guidance, PIC/S GMP Guide.
05 / 07
Achieving marketing authorization is the gateway to commercial success. We provide guidance through complex registration processes for pharmaceuticals, biologics, and medical devices.
Pre-approval and post-approval label reviews to ensure compliance with regional requirements for product cartons, inserts, package inserts, and Product Monographs. We support you in maximizing claims while maintaining regulatory alignment.
Regulatory classification, monograph compliance assessments, and label reviews for over-the-counter drug products and cosmetics, including Drug Identification Number (DIN) applications and cosmetic notifications.
Applicable Standards: ICH M4 (CTD), FDA 21 CFR Parts 314 (NDA), 601 (BLA), 814 (PMA), 807 (510(k)), EU MDR 2017/745, IVDR 2017/746, Health Canada Medical Devices Regulations, Natural Health Products Regulations, Food and Drug Regulations, ISO 13485 (medical devices), ISO 9001 (quality management).
06/ 07
Ensuring patient safety and compliance with pharmacovigilance (PV) obligations is critical throughout the product lifecycle.
Design and implementation of pharmacovigilance systems are provided to meet global requirements, including appointment of an EU Qualified Person for Pharmacovigilance (QPPV) and a US FDA Pharmacovigilance Responsible Person.
Procedures are established for adverse event collection, processing, evaluation, and expedited reporting to health authorities (e.g., FDA MedWatch, Health Canada Vigilance, Surveillance).
Signal detection activities are implemented, including literature scanning, data mining, and trend analysis, to identify and evaluate emerging safety signals.
Authoring and maintenance of the PSMF for EU compliance, ensuring it accurately reflects the PV system and is inspection ready.
Development of EU RMPs and FDA Risk Evaluation and Mitigation Strategies (REMS), including safety specification, pharmacovigilance plan, and risk minimization measures.
Preparation of Periodic Safety Update Reports (PSURs), Periodic Benefit-Risk Evaluation Reports (PBRERs), and Annual Summary Reports (ASRs) is provided in compliance with ICH E2C(R2) and regional requirements.
Applicable Standards: EU GVP Modules I through XVI, ICH E2A, E2B, E2C, E2D, E2E (pharmacovigilance), FDA 21 CFR Part 312 and 314 (IND and NDA safety reporting), Health Canada Pharmacovigilance requirements, WHO pharmacovigilance guidelines, ISO 9001 (quality management).
07 / 07
Robust quality systems underpin regulatory success. We provide comprehensive support to establish, maintain, and continuously improve quality and compliance posture.
Development and implementation of GMP, GLP, GCP, GDP, GVP, and GACP compliant quality systems, including policies, procedures, and work instructions tailored to your organizational structure.
Design and optimization of quality processes for deviation management, root cause analysis, CAPA implementation, and change control to ensure effective issue resolution and continuous improvement.
Preparation and review of annual Product Quality Reviews (PQRs/APQRs), including analysis of quality trends and identification of opportunities for process and product improvement.
Comprehensive preparation for health authority inspections, including mock inspections, staff training, and document organization. We provide real-time support during FDA, Health Canada, and EMA inspections, including scribe services and response management.
Third-party audit services for suppliers, CMOs, and internal operations. We conduct gap analyses and provide remediation guidance to ensure compliance with global GMP, GLP, and GDP standards.
Development of recall procedures and management of product recall activities, including health hazard evaluations, recall strategy, and communication with health authorities and customers.
Applicable Standards: ICH Q9 (quality risk management), Q10 (pharmaceutical quality system), FDA 21 CFR Parts 210 and 211 (GMP), EU GMP Annex 1 (sterile products), Annex 11 (computerised systems), Annex 15 (qualification and validation), Health Canada GMP guidelines, PIC/S GMP Guide, ISO 9001, ISO 13485, ISO 14644, ISO 17025, ISO 14698, WHO GACP guidelines, EU GACP guidelines (EMEA/HMPC/246816/2005), Health Canada Cannabis Regulations.
For more details or to discuss your project requirements, please reach out to us. Your query will be handled with complete confidentiality and we will ensure a prompt response.
You cannot copy content of this page
